SHANGHAI, Oct. 20, 2025 /PRNewswire/ — As a technology company committed to “making connectivity accessible to everyone,” UNISOC is working to bridge the global digital divide through innovation.

In today’s connected era, smartphones, wearables, and smart devices have become essential to how we live, work, and play. Yet, many people still cannot enjoy the convenience of high-quality connectivity. Research indicates that around 3.1 billion people remain offline, accounting for 38% of the global population — and 1.4 billion people aged 15 and above cannot afford a $30 smartphone. These figures highlight the gap between the promise of technology and its accessibility in reality.

UNISOC believes that connection is about more than technology— It shortens distances, empowers communication, and gives innovation true meaning. It also can carry warmth. Guided by its mission “Innovating for a better world” UNISOC strives to make intelligent living accessible to all through inclusive, people-centered technology.

Exploring More Possibilities of Connection——

Empowering Smart Experience Worldwide
In India, UNISOC powered the realme C53, enabling users to enjoy a 100-million-pixel ultra-clear imaging experience for just ₹10,000. In Southeast Asia, UNISOC partnered with ZTE nubia to launch an affordable light-flagship gaming phone priced at only ₹30,000. Equipped with the UNISOC Miracle Gaming Engine, players can enjoy top-10 global mobile games with stable, high frame rate and smooth performance.

Entertainment, once limited by price, is now open to everyone.

Bringing High-quality Imaging Within Reach
Beyond gaming, UNISOC’s imaging engine empowers ordinary users to capture cinematic-quality photos and videos. Whether it’s a sunset on the road or laughter among friends, every moment can be vividly and accurately preserved.

Connecting Innovation with Humanity
From imaging to gaming, from smartphones to wearables, UNISOC continues to focus on connection, using innovation to close the distance between people and technology. We believe true technology is not only about performance breakthroughs—but also about human warmth.

Connect to Innovation: This is UNISOC——Making Every Connection Filled with Humanity and the Power of Innovation.

WUHU, China, Oct. 20, 2025 /PRNewswire/ — As the global automotive industry accelerates toward a green, low-carbon future, corporate social responsibility has evolved — now defined by sustainable practices fostering harmony between people, society, and nature. As a globally recognized automotive brand, Chery continues to drive this vision through long-term, tangible actions uniting technology, humanity, and nature in balance.

On October 20, the third “Ride Green Life” Charity cycling event officially took place along the Yangtze River in Wuhu. As a key event of the 2025 Chery International User Summit, it brought together nearly 3,000 riders from around the world under the theme “Co-Create, Co-Define”, turning every ride into a pledge for the planet and setting a new benchmark for sustainable mobility.

Three Years Running: Evolving a Global Green Culture

Now in its third year, Chery’s “Ride Green Life” has evolved from a corporate initiative into a global green movement, fostering shared awareness and cross-border participation. Continuing the “Green Ride + Public Good” dual-drive model, this year’s event deepened collaboration with the International Union for Conservation of Nature (IUCN), integrating the ride into the global ecological protection network.

During the event, Chery announced the renewal of its three-year strategic partnership with UNICEF, committing an additional USD 6 million to support education in under-resourced regions worldwide. This initiative further strengthens Chery’s integrated “Green Mobility – Ecological Protection – Educational Equality” responsibility ecosystem, empowering children around the globe to build a brighter future.

Global Resonance: Inspiring a Shared Green Vision

The event gathered distinguished guests including Tarek Souei, CEO of the Asian Para Games Organizing Committee; Satrio Adi Wicaksono from the IUCN Asia Office; Myo-Zin Nyunt and Amakobe Sande from UNICEF; Shen Xiaomeng, Vice-Rector of the United Nations University (Europe); as well as officials and diplomats from Chile, Vietnam, Mexico, and South Africa. Cultural volunteers in traditional attire from different countries paraded together — from European tailcoats to Indonesian batik, Mexican ponchos, and African prints — forming a vivid tableau of global harmony and cultural unity.

In his address, Mr. Yin Tongyue, Chairman of Chery Group, stated:

“Ride Green Life is a philanthropic practice that Chery has been upholding for many years. This year’s cycling event is bigger in scale and more diversified. We aim to make Ride Green Life an influential, environmentally friendly public campaign, convey the Green idea and join hands with more people to protect our common home.”

This year’s event also received official certification from the China Cycling Association, officially joining the China Cycling Conference competition system — marking its transition from a corporate initiative to a nationally recognized green event.

Technology and Culture in Motion

At 9:30 a.m., as the flag dropped, a “green dragon” of cyclists set off along a scenic 9-km route passing the Yangtze Bend and Luhua Wetland — a dialogue between technology and nature in motion.

Among the riders, the cosplay contingent from Chery’s Cycling Association stood out as a remarkable highlight. Dressed as global icons such as Sun Wukong and Spider-Man, they embodied the creativity, passion, and global outlook of Chery’s young talent. The sight of the Eastern Monkey King cycling alongside Western superheroes vividly captured Chery’s open embrace of cultural diversity and its commitment to connecting East and West through innovation.

At the finish line, two Argos robotic dogs from Chery’s AiMOGA Robotics assisted in awarding medals, delighting participants with their agility and precision. This creative integration of robotics into an environmental ceremony vividly embodied Chery’s philosophy of technology coexisting with nature.

Extending Green Value Through a Complete Sustainable Ecosystem

Beyond the ride, Chery showcased its Hybrid Technology Pavilion, linking hybrid innovations with real-time carbon reduction data to highlight how technological progress fuels sustainability.

At the 2025 Chery International User Summit, Chery successfully built a multi-dimensional global communication ecosystem. By connecting diverse user communities — from technology and cycling to outdoor, environmental, public welfare, and animation circles — the summit created a seamless bridge from offline experiences to online engagement, from China’s home ground to the global stage. This approach not only amplified Chery’s global voice and actions but also fostered worldwide resonance around sustainability, spreading the spirit of “Ride Green Life” and green mobility across every corner of the world.

When nearly 3,000 cyclists rode along the Yangtze, they didn’t just complete a charity event — they advanced a movement. The third “Ride Green Life” Charity cycling event stands as living proof of Chery’s deep-rooted ESG commitment and lasting dedication to sustainable development.

As the last rider crossed the finish line, a new journey began. On its path to becoming a global leader in green and intelligent mobility, Chery will continue to move forward — with technology as its vessel, and responsibility as its sail — toward a greener, shared future.

SINGAPORE, Oct. 20, 2025 /PRNewswire/ — Digital travel platform Agoda has unveiled a list of five airports in Asia that transform layovers into memorable experiences. These airports offer more than just transit, with attractions that cater to both short and long stops, inviting travelers to arrive early and enjoy or make the most of a transit stop.

In today’s fast-paced travel landscape, airports are evolving into vibrant hubs of activity. These airports are not just gateways but destinations themselves, offering a blend of cultural attractions, gastronomic discovery, entertainment for all ages, shopping, and relaxation during the journey.  From cultural exhibits to luxurious spas, travelers can immerse themselves in local flavors and attractions without leaving the airport grounds.

Here’s Agoda’s curated list of five unique airports in Asia that make a layover worthwhile:

1.      Seoul, South Korea, Incheon International Airport (ICN) 

Incheon International Airport is a cultural treasure trove. Visitors can explore the Incheon Airport Museum and stroll through Korean Cultural Street, where they can capture memories in traditional Hanbok attire. Nearby, the Paradise Casino and Wonderbox provide entertainment, accessible via a free shuttle. Golf enthusiasts can tee off at the Sky72 Golf Course, while movie lovers enjoy the on-site theater. Free transit tours offer a glimpse of Seoul’s vibrant culture.

2.      Koh Samui, Thailand, Samui International Airport (USM)

Embracing the island’s natural beauty, Samui International Airport features an open-air design that seamlessly blends with its surroundings. Travelers can indulge in shopping for exquisite Thai silk and explore lush gardens. With free snacks and a children’s play area, it’s a delightful retreat for families seeking a taste of tropical paradise.

3.      Hong Kong, China, Hong Kong International Airport (HKG)

A marvel of modernity, Hong Kong International Airport offers the Aviation Discovery Centre and SkyDeck for aviation enthusiasts. The 4D Extreme Screen Cinema and Sky City provide thrilling entertainment, while the open-air Sky Garden offers a serene escape with stunning views.

4.       Kuala Lumpur, Malaysia, Kuala Lumpur International Airport (KUL)

The KLIA Jungle Boardwalk is a hidden gem, featuring an indoor rainforest complete with a waterfall. Movie lounges and a gym offer relaxation and fitness options, making it a versatile stop for travelers seeking both adventure and tranquility.

5.       Bali, Indonesia, Ngurah Rai International Airport (DPS)

Reflecting the island’s rich heritage, Ngurah Rai International Airport captivates with its Balinese architectural style and cultural performances. Travelers can unwind with traditional Balinese spa treatments, offering a rejuvenating experience before or after their journey.

Andrew Smith, Senior Vice President, Supply at Agoda, shared, “Airports in Asia are more than just transit points; they are gateways to the heart and soul of their destinations. Whether travelers are beginning their adventure or wrapping up their holiday, Agoda’s extensive flight offerings make it easier for travelers to explore these unique airports and enjoy a seamless journey filled with discovery and delight.”

Agoda’s extensive offerings, including over 6 million holiday properties, more than 130,000 flight routes, and over 300,000 activities, make it easy to plan a seamless travel experience. Visit Agoda.com or discover the best deals on Agoda’s mobile app today.

LONDON, Oct. 20, 2025 /PRNewswire/ — Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries.

This strategic move enhances Accord B.V.’s commitment to improving global access to plasma-derived medicines and strengthens its ability to meet the increasing demand for life-saving plasma therapies worldwide.

Prothya Biosolutions is one of Europe’s leading plasma fractionators, operating major facilities in Amsterdam and Brussels, along with plasma collection centres across Hungary. The company employs approximately 1,200 skilled professionals.

Advancing Global Access to Plasma

The integration of Prothya into Accord B.V., marks a significant expansion of Accord’s plasma capabilities. By combining Prothya’s proven expertise in Europe with Intas’s large-scale fractionation infrastructure in India, the organisation will accelerate the development and availability of essential plasma-derived medicinal products (PDMPs) for patients in multiple regions.

“Our goal is to ensure that patients who depend on plasma-derived therapies can access reliable and high-quality treatments,” said Paul Tredwell, Global CEO of Accord Healthcare. “Together with Prothya, we are better positioned to address the growing global need for plasma-derived medicines, providing patients worldwide with critical, often under-prescribed therapies.”

About Accord Healthcare

Headquartered in the United Kingdom, Accord Healthcare is one of the fastest-growing pharmaceutical companies in Europe. It boasts one of the largest market footprints among European generic and biosimilars companies, selling medicines in over 85 countries worldwide.

This global reach allows Accord to provide essential, affordable medicines to national health systems, assisting healthcare professionals in improving patient lives worldwide.

Accord is committed to being agile and inventive, continually seeking to enhance products and improve patient access. The company is driven to think differently and deliver more for the benefit of patients everywhere.

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of the Company’s human epidermal growth factor receptor 2 (HER2)-directed ADC trastuzumab botidotin (also known as A166) trastuzumab botidotin versus trastuzumab emtansine (T-DM1) in HER2-positive unresectable or metastatic BC was presented as an oral report by Professor Xichun Hu from Fudan University Shanghai Cancer Center (Presentation # LBA24, Proffered paper session 1: Breast cancer, metastatic).

Trastuzumab botidotin is a HER2-targeted ADC composed of a cytotoxic drug (Duostatin-5, anti-microtubule agent) with site-specific conjugation to trastuzumab via a stable protease-cleavable valine-citrulline linker. The unique linker is stable in plasma and selectively cleaved by lysosomal cathepsin B that is up-regulated in cancer cells.

In this study, a total of 365 patients with HER2+ unresectable or metastatic BC who had received at least one prior anti-HER2 therapy were randomized (1:1) to receive trastuzumab botidotin or T-DM1. 53% of patients had received ≥2 lines of anti-HER2 therapy, 61% of patients had HER2 Immunohistochemistry (IHC) 3+, and 60% of patients had been treated with TKIs, particularly pyrotinib (56%). As of April 26, 2025, median follow-up was 14.9 months.

Median PFS was significantly longer in trastuzumab botidotin than in T-DM1 (11.1 months vs 4.4 months; HR: 0.39, 95% CI, 0.30-0.51, p<0.0001). PFS benefit with trastuzumab botidotin was consistently observed regardless of prior lines of anti-HER2 therapy (HR 0.36, 95% CI, 0.25-0.53, for 1 prior line; HR 0.39, 95% CI, 0.28-0.56, for ≥2 prior lines).

ORR by blinded independent central review (BICR) was 76.9% vs 53.0%.

A trend toward benefit in OS was observed in trastuzumab botidotin (HR 0.62; 95% CI, 0.38-1.03).

Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 69.8% of patients in trastuzumab botidotin and 63.7% in T-DM1. The most common TEAEs associated with dose reduction were ocular AEs for trastuzumab botidotin, and were platelet count decreased for trastuzumab emtansine. Only two patients permanently discontinued trastuzumab botidotin due to TEAE. No on-treatment deaths were observed in trastuzumab botidotin, compared with 1.6% in T-DM1, all of which were considered unrelated to treatment.

As a conclusion, this second head-to-head trial comparing T-DM1 with other anti-HER2 regimens demonstrated that trastuzumab botidotin statistically improved PFS with an ORR of 76.9% vs 53.0%. PFS benefit with trastuzumab botidotin was consistently observed regardless of prior lines of anti-HER2 therapy. Ocular AEs were also manageable.

“Professor Xichun Hu, National Lead Principal Investigator from Fudan University Shanghai Cancer Center:”Trastuzumab botidotin effectively balances safety and efficacy through its unique molecular design, reducing the incidence of interstitial lung disease and hematologic toxicity. According to research data, trastuzumab botidotin demonstrated significant survival benefits in the pivotal Phase III trial, with an overall manageable safety profile, providing a new important treatment option for pretreated HER2+ BC patients. These positive results also offer robust evidence-based support for personalized treatment and updates to clinical practice guidelines.”

About Trastuzumab botidotin

Trastuzumab botidotin is a differentiated HER2 ADC to treat advanced HER2+ solid tumors. As an innovative HER2 ADC developed by the Company, it conjugates a novel, monomethyl auristatin F (MMAF) derivative (a highly cytotoxic tubulin inhibitor, Duo-5) via a stable, enzyme-cleavable linker to a HER2 monoclonal antibody with a DAR of 2. Trastuzumab botidotin specifically binds to HER2 on the surface of tumor cells and is internalized by tumor cells, releasing the toxin molecule Duo-5 inside the cell. Duo-5 induces tumor cell cycle arrest in the G2/M phase, leading to tumor cell apoptosis. After targeting HER2, trastuzumab botidotin can also inhibit the HER2 signaling pathway; it has antibody-dependent cell-mediated cytotoxicity (ADCC) activity.

Based on the results of a multi-center, randomized, open-label, controlled, Phase 3 KL166-III-06 study, trastuzumab botidotin was approved for marketing by the NMPA in for adult patients with unresectable or metastatic HER2 positive BC who have received one or more prior anti-HER2 therapy. At a pre-specified interim analysis, trastuzumab botidotin demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of PFS as assessed by the BICR compared with T-DM1[; the beneficial trend for OS of trastuzumab botidotin was also observed.

Currently, the Company has initiated an open, multi-center Phase 2 clinical study of trastuzumab botidotin in the treatment of HER2+ unresectable or metastatic BC that previously received a topoisomerase inhibitor ADC.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 4 projects have been approved for marketing, 1 projects are in the NDA stage and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 1 ADC project approved for marketing and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.

The first “GPS + Laser” hybrid rangefinder redefining how golfers see and play the game.

CITY OF INDUSTRY, Calif., Oct. 20, 2025 /PRNewswire/ — MILESEEY Golf proudly announces that its groundbreaking hybrid rangefinder, the GenePro G1, has been featured in TIME’s “The Best Inventions of 2025: Special Mentions.”
Recognized for its innovative integration of AMOLED full-color touchscreen and built-in global course mapping, the GenePro G1 stands out as a true “GPS + Laser” hybrid that brings a smarter, faster, and more intuitive experience to every golfer’s round.

Redefining the Rangefinder Experience

“We didn’t just add GPS to a laser rangefinder — we rebuilt how golfers make decisions,” said a MILESEEY Golf spokesperson.
“The GenePro G1 lets players see the full picture and hit with confidence, all from one natural motion. It’s precision made visible.”

Why the GenePro G1 Stands Out

• True Hybrid Experience: Combines a 2.13″ AMOLED touchscreen with 43,000+ preloaded global courses, allowing golfers to view hole layouts, hazards, and front/middle/back distances without relying on a phone or watch.
• Professional-Grade Laser Precision: Measures up to 1,300 yards with ±0.5-yard accuracy, featuring vibration feedback and 600-yard flag-lock capability.
• SmartSlope™ Compensation: Factors in slope, temperature, humidity, and altitude to deliver true “play-like” yardages and smarter club choices.
• Ball-to-Pin™ (P2P) Mode: Instantly measure from your ball to the pin even when terrain blocks direct sight lines—speeding up play and aiding pre-shot planning.
• Crystal-Clear Optics: With 6x magnification, 7.5° field of view, and ~90% light transmission, the G1 delivers a bright, steady, and comfortable viewing experience.

International Recognition

TIME highlighted the GenePro G1 as a “high-tech golf rangefinder,” emphasizing its AMOLED touchscreen and global course database that merge GPS intelligence with laser precision.
This acknowledgment underscores the growing trend of technology enhancing on-course decision-making — and cements G1’s role as a category pioneer.

Availability

The GenePro G1 is now available on the MILESEEY Golf official website and select authorized retailers.
For more information, visit www.mileseeygolf.com or follow @MileseeyGolf on social media.

About MILESEEY Golf

Founded in 2009, MILESEEY is a global leader in high-precision optical and measurement technologies, serving over 10 million users across 100+ countries.
With full-stack R&D capabilities — from laser and optical modules to intelligent algorithms and industrial design — MILESEEY Golf creates innovative tools that help golfers of all levels see clearer, play faster, and score smarter.

Media Contact

MILESEEY Golf PR & Media Relations
17800 Castleton St, Suite 665, City of Industry, CA 91748, USA 
Email: noahharrington@mileseey.com 
Social Media: @MileseeyGolf (YouTube / Facebook / TikTok / Instagram)